Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00270725
Recruitment Status : Withdrawn (Enrollment never initiated, study withdrawn.)
First Posted : December 28, 2005
Last Update Posted : February 28, 2017
United States Agency for International Development (USAID)
Information provided by:
Boston University

Brief Summary:
The purpose of this study is to determine the impact of anti-HIV treatment on the work attendance of employed people in South Africa. The study will enroll participants from a large manufacturing and distribution firm in South Africa.

Condition or disease
HIV Infections

Detailed Description:

Little is known about the economic benefits of providing antiretroviral therapy (ART) for HIV infected patients in sub-Saharan Africa and other resource-limited areas. In South Africa, an increasing number of private sector firms are providing access to ART for their employees. One of the barriers to such action, however, is the lack of available information on the success of ART in restoring workers to full productivity, retaining skilled employees in the workforce, and reducing the costs of medical care and death and disability benefits. HIV infected employees on ART may be absent from work less often than untreated HIV infected employees, but more often than HIV uninfected employees. This study will collect data from an independent HIV/AIDS disease treatment program and a large private sector employer in Johannesburg, South Africa to estimate the benefits and costs for businesses to provide ART to eligible employees.

The study will combine individual-level medical outcome and treatment cost data from the treatment program with data on employee work attendance and retention in the workforce from the participating employer. The work attendance of HIV infected employees enrolled in the HIV/AIDS treatment program (index participants) who are either taking ART or receiving pre-ART care will be compared with each other and with that of HIV uninfected employees. There are no study visits associated with this study; all data will be collected from medical records maintained by the HIV/AIDS treatment program and the participants' employer. The financial costs and benefits of the treatment program for the participating company will also be estimated.

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS
Actual Study Start Date : July 1, 2005
Actual Primary Completion Date : July 1, 2005
Actual Study Completion Date : July 1, 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
see elig

Inclusion Criteria for All Participants:

  • Employed by participating company for at least 1 year prior to study entry

Inclusion Criteria for Index Participants:

  • Enrolled in the HIV/AIDS treatment program offered by the participating company

Exclusion Criteria for Index Participants:

  • Enrolled in the HIV/AIDS treatment program prior to 01/01/04 or after 06/30/05

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00270725

South Africa
Health Economics Research Office, Helen Joseph Hospital
Johannesburg, Gauteng, South Africa, 2092
Sponsors and Collaborators
Boston University
United States Agency for International Development (USAID)
Principal Investigator: Sydney B. Rosen, MPA Boston University

Additional Information:
Responsible Party: Sydney Rosen, Boston University Identifier: NCT00270725     History of Changes
Other Study ID Numbers: RTC-BU-01
First Posted: December 28, 2005    Key Record Dates
Last Update Posted: February 28, 2017
Last Verified: February 2017

Keywords provided by Boston University:
Labor productivity
Antiretroviral therapy
South Africa

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases